Developing the first class of ADCs based on NMT inhibition
Myricx Bio is a UK biotech company focused on discovering and developing a novel class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. Founded on world-leading NMT biology and chemistry research, Myricx is advancing a pipeline of NMTi-ADC programs against validated oncology targets including B7-H3 and HER2 toward clinical development.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account